We are live on ! Find out more
SGH

Sivik Global Healthcare Portfolio holdings

AUM $132M
1-Year Est. Return 24.1%
This Fund
S&P 500
This Quarter Est. Return
+10.43%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$260M
AUM Growth
+$45.7M
Cap. Flow
+$28M
Cap. Flow %
10.77%
Top 10 Hldgs %
28.77%
Holding
76
New
17
Increased
25
Reduced
14
Closed
15

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$6.57M
2
MRK icon
Merck
MRK
+$6.28M
3
AZN icon
AstraZeneca
AZN
+$5.4M
4
COR icon
Cencora
COR
+$5.05M
5
CI icon
Cigna
CI
+$4.33M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$7.1M
2
UHS icon
Universal Health Services
UHS
+$6.51M
3
CAH icon
Cardinal Health
CAH
+$5.01M
4
SNN icon
Smith & Nephew
SNN
+$3.81M
5
UNH icon
UnitedHealth
UNH
+$3.46M

Sector Composition

Rank Sector Weight
1 Healthcare 93.84%
2 Energy 1.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMS icon
51
Fresenius Medical Care
FMS
$12.7B
$1.76M 0.68%
35,000
-15,000
-30% -$761K
ENDP
52
DELISTED
Endo International plc
ENDP
$1.7M 0.65%
+180,000
New +$1.21M
AKRX
53
DELISTED
Akorn Inc
AKRX
$1.66M 0.64%
100,000
+9,901
+11% +$152K
ONCE
54
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.66M 0.64%
+20,000
New +$1.54M
XENT
55
DELISTED
Intersect ENT, Inc
XENT
$1.61M 0.62%
43,000
-22,000
-34% -$864K
CHRS icon
56
Coherus Oncology
CHRS
$187M
$1.4M 0.54%
+100,000
New +$1.43M
NVRO
57
DELISTED
NEVRO CORP.
NVRO
$1.28M 0.49%
16,002
-18,998
-54% -$1.58M
PBYI icon
58
Puma Biotechnology
PBYI
$454M
$1.18M 0.45%
20,000
-5,000
-20% -$290K
DXCM icon
59
DexCom
DXCM
$33.8B
$1.03M 0.4%
+43,600
New +$924K
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$5.07B
$723K 0.28%
+47,351
New +$844K
PTLA
61
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$567K 0.22%
+15,000
New +$574K
ABBV icon
62
AbbVie
ABBV
$442B
– –
-75,000
Closed -$7.1M
BDX icon
63
Becton Dickinson
BDX
$49.4B
– –
-10,250
Closed -$2.17M
BPMC
64
DELISTED
Blueprint Medicines
BPMC
– –
-20,000
Closed -$1.83M
CAH icon
65
Cardinal Health
CAH
$56.2B
– –
-80,000
Closed -$5.01M
CHE icon
66
Chemed
CHE
$7.02B
– –
-7,500
Closed -$2.05M
HAE icon
67
Haemonetics
HAE
$3.97B
– –
-26,893
Closed -$1.97M
HCA icon
68
HCA Healthcare
HCA
$89.1B
– –
-25,000
Closed -$2.42M
NBIX icon
69
Neurocrine Biosciences
NBIX
$16.5B
– –
-30,000
Closed -$2.49M
RVTY icon
70
Revvity
RVTY
$12.9B
– –
-45,000
Closed -$3.41M
SNN icon
71
Smith & Nephew
SNN
$12.6B
– –
-100,000
Closed -$3.81M
TDOC icon
72
Teladoc Health
TDOC
$1.24B
– –
-40,000
Closed -$1.61M
TECH icon
73
Bio-Techne
TECH
$11.2B
– –
-80,000
Closed -$3.02M
UHS icon
74
Universal Health Services
UHS
$9.94B
– –
-55,000
Closed -$6.51M
AVXS
75
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-15,000
Closed -$1.85M
1 2
3

Similar funds

AFP
ATX Financial Planning Austin, Texas $132M AUM
TCPW
Twin City Private Wealth Winston-Salem, North Carolina $132M AUM 11.31% 1-Year Est. Return
PCGDR
Pangea Capital Gestao de Recursos Rio De Janeiro $131M AUM
ACM
Alcosta Capital Management San Ramon, California $131M AUM 34.7% 1-Year Est. Return
9C
9823 Capital Dallas, Texas $132M AUM
STFP
Signal Tree Financial Partners Copley, Ohio $132M AUM 15.43% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $131M AUM 7.53% 1-Year Est. Return
AC
Aldebaran Capital Carmel, Indiana $131M AUM 34.7% 1-Year Est. Return

Sivik Global Healthcare's Q2 2018 Portfolio in Review

As of Q2 2018, Sivik Global Healthcare held 76 positions worth $260M, up 21% from $214M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Sivik Global Healthcare deployed $28M of net new capital in Q2 2018, opening 17 new positions and adding to 25 existing holdings. Its largest new stake was Eli Lilly: 80,000 shares worth $6.83M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was UnitedHealth, an estimated $3.46M trimmed.

  • Sivik Global Healthcare's largest Q2 2018 buy was Eli Lilly: 80,000 shares worth $6.83M.
  • Sivik Global Healthcare added most to Cencora in Q2 2018, an estimated $5.05M increase.
  • Sivik Global Healthcare's biggest Q2 2018 reduction was UnitedHealth, cutting an estimated $3.46M.
  • Sivik Global Healthcare fully exited AbbVie in Q2 2018, selling an estimated $7.1M.
  • Sivik Global Healthcare's ten largest holdings make up 29% of its $260M portfolio in Q2 2018.
  • Sivik Global Healthcare opened 17 new positions and closed 15 in Q2 2018.
  • Sivik Global Healthcare's portfolio value rose 21% quarter-over-quarter to $260M.

Based on Sivik Global Healthcare's 13F filing for Q2 2018, filed 6 Aug 2018.